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PURPOSE: Hodgkin’s lymphoma survivors (HLSs) have an elevated risk for cardiovascular diseases that appear several years after
radiotherapy. This study examined the time-dependent development and evolution of valvular and myocardial function related to
treatment with mediastinal radiotherapy and anthracyclines in HLSs.
PATIENTS AND METHODS: In 1993, echocardiography was performed in 116 HLSs median 10 years (range 6–13 years) after treatment
with mediastinal radiotherapy. None of the 116 patients had valvular stenosis in 1993 whereas 36 (31%) had moderate valvular
regurgitation. In 2005–2007, 51 of 57 invited patients were included in a second echocardiographic study – median 22 years (range
11–27 years) after treatment. Of these patients, 28 (55%) had also received anthracyclines. The patients were selected on the basis
of the presence or absence of moderate valvular regurgitation in 1993.
RESULTS: The second echocardiographic study demonstrated that 10 out of 27 (37%) patients with only mild or no aortic or mitral
regurgitation in 1993 had developed moderate regurgitation in either or both the aortic or mitral valve. Of the 24 patients with
moderate (n¼23) or severe (n¼1) regurgitation in the aortic or mitral valve in 1993, 8 (33%) had progressed to severe
regurgitation, developed moderate regurgitation in a previously normal or mild regurgitant valve or had received valvular
replacement. In total, of all patients, 20 (39%) had developed mild to severe aortic stenosis and 3 patients had received valvular
replacement. In a multiple linear regression the use of anthracyclines predicted left ventricular remodelling between ECHO 1993 and
2005 as demonstrated by increased left ventricular end systolic diameter (b ¼0.09 (95% CI 0.01–0.17), P¼0.04) and reduced
thickness of the left ventricular posterior wall (b ¼ 0.18 (95% CI  0.33 to  0.03), P¼0.02) and interventricular septum
(b ¼ 0.16 (95% CI  0.30 to  0.03), P¼0.02).
CONCLUSION: Given the progressive nature of valvular dysfunction and left ventricular remodelling 20–30 years after diagnosis, we
recommend life-long cardiological follow-up of HLSs treated with mediastinal radiotherapy.
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Hodgkin’s lymphoma is one of the most common cancers in young
adults; an annual incidence of 3 per 100000 was recorded in the
United States in 2004 (National Cancer Institute, 2008). Modern
radiotherapy and chemotherapy used either alone or in combina-
tion have increased the 5-year overall survival rate to 85% (Boice,
2007). However, Hodgkin’s lymphoma survivors (HLSs) have an
elevated risk of developing long-term sequelae, including second-
ary malignancies and cardiovascular diseases (Hudson et al, 1998;
Aleman et al, 2007; Heidenreich et al, 2007; Swerdlow et al, 2007).
Several reports indicate that cardiovascular diseases appear more
than 10 years after treatment, including coronary artery disease
(CAD), congestive heart failure due to cardiomyopathy, valvular
disease, and constrictive pericarditis (Lund et al, 1996; Hudson
et al, 1998; Heidenreich et al, 2003, 2007; Hull et al, 2003; Adams
et al, 2004; Aleman et al, 2007; Swerdlow et al, 2007). In addition,
increased prevalences of calcification, stenosis in the great arteries,
and stroke have been reported (King et al, 1999; Bowers et al, 2005;
Apter et al, 2006; Patel et al, 2006). The main cause of
cardiovascular disease in HLSs is thought to be radiotherapy.
Furthermore, chemotherapy, especially anthracycline treatment,
induces cardiomyopathy and aggravates cardiac disorders by
various mechanisms (Singal and Iliskovic, 1998; Meinardi et al,
2000; Wallace, 2003; Wouters et al, 2005).
The incidence of valvular dysfunction has been reported to
increase during the second decade after mediastinal radiotherapy
for Hodgkin’s lymphoma (Heidenreich et al, 2003; Hull et al, 2003;
Adams et al, 2004). After 20 years, 6–15% of HLS have moderate
or severe valvular regurgitation in the aortic or mitral valve, and a
few present with aortic stenosis. In 1993, our group invited HLSs
treated at the Norwegian Radium Hospital between 1980 and 1988
to perform echocardiography (ECHO 1993) if they fulfilled the
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sfollowing criteria: mediastinal radiotherapy (with or without
chemotherapy), age o50 years at diagnosis, and relapse free survival
for 45y e a r s( L u n det al, 1996). Of the 116 patients participating
(median observation time: 10 years), 36 (31%) demonstrated
moderate regurgitation in 40 valves, primarily the aortic and mitral
valves. Eighty individuals had no or mild regurgitation in 1993. No
patients had developed valvular stenosis in 1993.
The cross-sectional nature of previously published studies
makes it difficult to assess the time-dependent progression of
valvular dysfunction in the individual patient. Therefore, during
2005 we performed a follow-up study with echocardiographic
examinations in a subgroup of patients examined in 1993 by Lund
et al (ECHO 2005) with the objective to assess valvular and
ventricular changes between the examinations in 1993 and 2005. In
2005, our primary interest was to assess the post-1993 develop-
ment of moderate regurgitations, conditions where regular
echocardiographic follow-up is recommended according to guide-
lines (Bonow et al, 2006). Thus, all surviving patients with
moderate and severe regurgitations in 1993 were recruited to
participate in ECHO 2005. Mild regurgitation is frequently
observed in the general population and not regarded as pathology.
From the group of 80 patients without or with only mild valvular
regurgitation we invited 25 age- and gender-matched survivors for
comparison of changes.
PATIENTS AND METHODS
Patients
Of the 36 patients with moderate regurgitation in 1993, 4 had died
(3 from cancer other than Hodgkin’s lymphoma, 1 from CAD). A
total of 57 patients were invited for ECHO 2005; all patients still
alive with moderate regurgitation in 1993 (n¼32) and 25 patients
with no or mild regurgitation in 1993. Six patients declined. Of the
51 remaining participants, 28 had at least one valve with moderate
or severe regurgitation at ECHO 1993. Four patients had either
moderate pulmonal (n¼2) or tricuspid (n¼2) regurgitation but
no or only mild aortic or mitral regurgitation. Thus, 24 patients
had moderate mitral and/or aortic regurgitation whereas the
remaining 27 patients demonstrated no (n¼14) aortic or mitral
regurgitation or only mild (n¼13) aortic and/or mitral regurgita-
tion. Before the reexamination at ECHO 2005 three patients had
received mechanical valve implants (for aortic regurgitation, aortic
stenosis, and mitral regurgitation, respectively), and for these
patients the last preoperative echocardiography was included in
the ECHO 2005 analysis as the second follow-up examination.
Disease and treatment characteristics were obtained from
medical records, including type of radiotherapy (mantle field vs
mediastinal field only) and details regarding the use of additional
chemotherapy (Table 1). Radiotherapy was delivered in fractional
doses of 1.8 or 2.0Gy 5 days per week with a median dose of
40.0Gy (range 24–44Gy) to the mediastinum. No subcarinal
blocks or cardiac shields were used. Anterior and posterior fields
were weighted equally. Further treatment details are described
elsewhere (Lund et al, 1996).
All patients completed a questionnaire regarding lifestyle
parameters (smoking, physical activity) and underwent a clinical
examination. Chronic medication, cardiovascular events, and
cardiac risk factors were recorded. A cardiovascular event was
defined as myocardial infarction, percutaneous coronary inter-
vention or coronary artery bypass graft surgery, valvular surgery,
stroke, or transitory ischaemic attack.
Blood samples
Non-fasting blood was sampled between 0900 hours and 1200
hours. Plasma was stored at  701C for later determination of CRP
and pro-Brain Natriuretic Peptide (pro-BNP; Roche Diagnostics,
Oslo, Norway), total cholesterol, low-density lipoprotein cholesterol
(LDL), high-density lipoprotein cholesterol (HDL), and triglycerides.
Echocardiography
We performed two-dimensional (2D) transthoracic echocardio-
graphy with a Vivid 7 scanner (GE Vingmed Ultrasound, Horten,
Norway). Three consecutive heart cycles from the parasternal, long
axis, short-axis, apical four chamber, and subcostal views were
obtained. The digital loops were stored and analysed by EchoPac
Table 1 Demographic and clinical characteristics of the study group
Number of patients (n¼51)
Age (years)
At cancer diagnosis 26 (14–42)
At current examination 50 (35–63)
Observation time 22 (11–27)
Females; n (%) 34 (67)
Cancer stage; n (%)
Stages I and II 40 (78)
Stages III and IV 11 (22)
Relapses; n (%) 6 (12)
Radiotherapy
Radiation dose (Gy) 40.0 (27.0–44.0)
Mantle field; n (%) 43 (84)
Mediastinal field only; n (%) 8 (16)
Chemotherapy
Chemotherapy; n (%)
a 36 (71)
Received anthracyclines; n (%) 28 (55)
Dose of adriamycin (mg)
a 320 (110–480)
ChlVPP/ABOD; n (%) 23 (45)
ChlVPP only; n (%) 5 (10)
ABOD only; n (%) 4 (8)
ChlVPP/EBVP; n (%)
b 1 (2)
Other regimes; n (%) 3 (6)
Current smoker; n (%) 14 (27)
Self-reported comorbidities; n (%)
History of hypothyroidism 34 (67)
History of hypercholesterolaemia 10 (20)
Diabetes 1 (4)
Cardiovascular disease 15 (29)
Coronary disease 9 (18)
Stroke or TIA 3 (6)
Valvular surgery 3 (6)
Clinical findings
Systolic blood pressure (mmHg) 123 (85–156)
Diastolic blood pressure (mmHg) 72 (52–95)
Hypertension; n (%)
c 13 (25)
Body mass index (kg/m
2) 24.0 (17.4–34.2)
Blood samples
Cholesterol (mmoll
 1) 5.3 (3.4–7.0)
HDL cholesterol (mmoll
 1) 1.3 (0.8–2.3)
LDL-cholesterol (mmoll
 1) 3.6 (1.8–4.7)
Triglycerides (mmoll
 1) 1.1 (0.6–3.7)
CRP (mgl
 1) 2.35 (0.20–43)
proBNP (pmoll
 1) 21.0 (3.7–201)
Medians and ranges are given for all continuous parameters. ChlVPP¼chlorambucil,
vinblastin, procarbazine, prednisolon; ABOD¼adriamycin, bleomycin, vincristin,
dacarbazine; EBVP¼epirubicin, bleomycin, vinblastin, prednisolon.
aIncluding che-
motherapy for relapses.
bEpirubicin was given to one patient at a total dose of
720mg.
cHypertension: systolic blood pressure X140mmHg or a diastolic blood
pressure X90mmHg or the use of antihypertensive medication in order to lower
blood pressure.
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ssoftware (GE Vingmed Ultrasound). In M-mode, we recorded
measurements of left atrial (LA) diameter, left ventricular end-
diastolic and end-systolic diameters (LVEDD and LVESD,
respectively), left ventricular posterior wall (LVPW), interventri-
cular septum thickness (IVSd), and left ventricular shortening
fraction (LV-SF). Cardiac index (CI) was calculated from cardiac
stroke volume, body height, and body weight. Left ventricular
ejection fraction (LVEF) was assessed by the modified Simpson’s
rule. LVEF and left ventricular end diastolic volume were
measured only in ECHO 2005. 2D and pulsed Doppler echocardio-
graphy were used to estimate valvular regurgitation and stenosis
(mild, moderate, or severe) according to published recommenda-
tions (Zoghbi et al, 2003; Bonow et al, 2006). Left ventricular
remodelling was defined as a thinning of ventricular walls and
dilatation of the ventricle but without any impairment in the
systolic function between ECHO 1993 to 2005. All examinations
were carried out according to a standardised protocol by
physicians and sonographers at the Department of Cardiology,
and all the data were interpreted by a single experienced
cardiologist, blinded for patient history (including the results
from ECHO 1993) and treatment.
Statistics
Data were expressed as means/medians with standard deviations
(s.d.)/range or as percentages. The Student’s t-test was used to
compare normally distributed continuous data. The Mann–
Whitney test was used for highly skewed continuous data. The
w
2-test was performed to compare categorical data between groups.
Differences in left ventricular function between ECHO 1993 and
ECHO 2005 were tested with the paired-samples t-test. Further-
more, for each patient, the changes (expressed as percentage
increase or decrease) in left ventricular parameters from ECHO
1993 to ECHO 2005 were calculated. The patients were then
grouped according to the previous use of anthracyclines, the
presence of aortic stenosis, cardiovascular disease, and gender.
Intergroup differences in echocardiographic parameters were
analysed with the independent-samples t-test. Pearson correlation
analysis was used to investigate the relationships between age, pro-
BNP, and CRP and echocardiographic variables. Multiple linear
regression analyses were performed with significant univariates
(Po0.10) as independent variables and with the percent changes in
each of the six echocardiographic variables as dependent variables.
Binary logistic regression was performed to investigate whether
any of the treatment-related or clinical parameters were associated
with aortic stenosis or new onset valvular regurgitation. A two-
tailed P value p0.05 was considered statistically significant. All
statistical analyses were performed with SPSS 14.0 (SPSS Inc.,
Chicago, IL, USA). The study was approved by the institution’s
protocol review committee. All the participants gave their
informed consent.
RESULTS
Hodgkin’s lymphoma had been diagnosed in stages I and II in 40
(78%) patients and in stages III and IV in 11 (22%) patients
(Table 1). The median age at diagnosis was 26 years (range 14–42
years), and 67% of the participants were women. Mantle or
mediastinal fields had been given to 43 and 8 of 51 patients,
respectively. The median dose to the mediastinum was 40.0Gy
(range 27–44Gy). A total of 36 patients received additional
chemotherapy, either as part of their primary treatment together
with radiotherapy or, in 6 patients (12%), as treatment for relapse.
Anthracyclines were given to 28 (55%) patients with a total median
adriamycin dose of 320mg (range 110–480mg) in 27 and 720mg
of epirubicin in 1 patient. The median time between diagnosis and
the second echocardiography was 22 years (range 11–27 years). At
ECHO 2005, 15 patients reported a preceding cardiovascular event.
Valvular dysfunction
Valvular regurgitation Of 14 patients with no evidence of aortic
or mitral regurgitation in 1993, only 1 remained unchanged at
ECHO 2005 (Table 2). Nine patients had developed only mild
whereas three developed moderate regurgitation in the aortic,
mitral valve or both, and one patient had an aortic valve
implantation due to aortic stenosis.
There were 13 patients with only mild regurgitation in either the
mitral or aortic valve in 1993. Only two patients remained
unchanged with respect to valvular regurgitation, but one
developed aortic stenosis. Four patients developed mild regurgita-
tion in a previously unaffected valve and seven patients had
progressed to moderate mitral and/or aortic regurgitation at ECHO
2005.
At ECHO 2005, 10 of the 27 patients (37%) without or with only
mild valvular regurgitation progressed to moderate regurgitation
in the aortic and/or mitral valve. In addition, 13 had new aortic
stenosis.
Twenty-three patients had moderate regurgitation in either or
both the aortic or mitral valve in 1993. Status remained unchanged
in 10 patients at ECHO 2005. Two patients had progressed to a new
moderate regurgitation in either the aortic or mitral valve. Four
patients went from moderate to severe regurgitation and one had
an aortic valve implantation due to regurgitation. One patient had
severe mitral regurgitation at ECHO 1993, which was treated with a
mechanical valve during follow-up. Thus, of the 24 patients with a
moderate or severe regurgitation in the aortic or mitral valve in
RV
LV
AV AO
LA
RV
LV AV
AO
LA
Figure 1 (A) In 1993 (7.5 years postradiotherapy), the aortic valve was
without pathology and opened completely. (B) In 2007 (21.5 years
postradiotherapy), echocardiography showed a thickened aortic valve,
which hardly opened during ventricular systole in a patient with severe
aortic stenosis. Abbreviations: AO, aorta; AV, aortic valve; LV, left ventricle;
LA, left atrium; RV, right ventricle.
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s1993, 8 (33%) had progressed to severe regurgitation, to moderate
regurgitation in another previous normal valve, or had performed
valvular surgery.
Aortic stenosis No aortic stenosis was demonstrated in 1993. In
contrast, at ECHO 2005, 20 out of 51 (39%) patients had developed
aortic stenosis (mild (13), moderate (3), and severe (4)) with an
estimated mean aortic valve area of median 1.6cm
2 (range 0.6–
3.2cm
2) and a mean valvular gradient of 11mmHg (range 5–
45mmHg) (Figure 1).
Binary logistic regression with the presence of aortic stenosis as
the dependent variable failed to show any relationship with
chemotherapy, the presence or absence of valvular regurgitation in
1993 or any of the clinical parameters given in Table 1. New-onset
valvular regurgitation did not demonstrate any relation to clinical
or treatment related parameters.
Appearance of the valves The appearance of both the aortic and
mitral valve was dominated by different degrees of degeneration
including leaflet thickening, reduced leaflet movements, and
calcification. Calcification was observed among those with
moderate/severe stenosis or regurgitation. The mean ejection
fraction was 54% (s.d. 7%) and mean left ventricular end diastolic
volume was 97ml (s.d. 31ml) indicating that mitral regurgitation
was due to organic involvement of the valve. Only two patients had
EF below 45% and these patients had moderate aortic regurgitation
and mild mitral regurgitation, respectively.
Left ventricular remodelling
Compared to ECHO 1993, the second echocardiography demon-
strated an increased LVESD (P¼0.02) and a reduced LV-SF
(P¼0.003; Table 3). Additionally, LA diameter was increased for
all participants in ECHO 2005 (Po0.001).
Multiple linear regression analyses were performed with
previous use of anthracyclines, age at ECHO 2005, cardiovascular
disease, and the presence of aortic stenosis as independent
variables. The use of anthracyclines was associated with increased
LVESD and impaired IVSd and LVPW indicating left ventricular
remodelling (Table 4). Additionally, increasing age at ECHO 2005
was associated with an independent effect on IVSd and CI.
Demonstration of aortic stenosis was associated with increased
LVEDD and LVESD.
Biochemical markers
CRP and pro-BNP was higher among patients with moderate or
severe aortic or mitral regurgitation in ECHO 2005 compared to
patients without valvular regurgitation (CRP: median 2.5mgl
 1
(range 0.2–43mgl
 1) and 1.1mgl
 1 (0.6–8.8mgl
 1), P¼0.015;
pro-BNP: median 24pmoll
 1 (range 4–201pmoll
 1) and
10pmoll
 1 (range 4–53pmoll
 1), P¼0.006). BNP correlated
positively with LVEDD (r¼0.36, P¼0.01), LVESD (r¼0.38,
P¼0.007) and negatively with EF (r¼ 0.29, P¼0.045).
Table 2 The development of aortic regurgitation, mitral regurgitation,
and aortic stenosis from 1993 to 2005–07
ECHO 2005
ECHO 1993
aortic or mitral
regurgitation
New or persistent
aortic or mitral
regurgitation
New aortic
stenosis
No 14
a Status unchanged 1
Mild only (new) 9
a 4
Moderate (new) 3 1
Implanted valve 1
a 1
Mild 13
b Status unchanged 2 1
Mild only (new) 4 1
Moderate (new) 7
b 5
Moderate 23 Status unchanged 10 3
Moderate
New 2 2
Persistent+new mild 6 2
Severe (new) 4
Implanted valve 1
Severe 1 Implanted valve 1
Total 51 51 20
aAlso includes two patients with moderate pulmonary regurgitation and one with
moderate tricuspid regurgitation.
bAlso includes one patient with moderate tricuspid
regurgitation.
Table 3 Echocardiographic examinations
Number of patients (n¼51) ECHO 1993 ECHO 2005 P value
LA (cm) 3.1 (0.6) 3.4 (0.6) o0.001
LVEDD (cm) 4.8 (0.5) 4.9 (0.5) 0.70
LVESD (cm) 3.2 (0.4) 3.4 (0.6) 0.02
IVSd (cm) 0.9 (0.2) 0.9 (0.2) 0.80
LVPW (cm) 0.8 (0.2) 0.8 (0.2) 0.78
LV-SF (%) 34.2 (4.7) 31.2 (6.3) 0.003
CI, (lmin
 1m
 2) 2.9 (0.5) 3.0 (0.7) 0.57
EF (%) 54 (7)
LVEDV (ml) 97 (31)
Means (standard deviations) are given for all continuous parameters. LA¼left atrium
diameter; LVEDD¼left ventricular end diastolic diameter; LVESD¼left ventricular
end systolic diameter; IVSd¼interventricular septum thickness; LVPW¼left
ventricular posterior wall; LV-FS¼left ventricular shortening fraction; CI¼cardiac
index; EF¼ejection fraction; LVEDV¼left ventricular end diastolic volume.
Table 4 Multiple linear regression analysis of factors involved in changes of left ventricular function from ECHO 1993 to ECHO 2005
Treatment with anthracyclines
(yes/no) Age at ECHO 2005 Cardiovascular disease (yes/no) Aortic stenosis (yes/no)
Echocardiographic
parameters b (95 % CI) P value b (95 % CI) P value b (95 % CI) P value b (95 % CI) P value
LVEDD 0.051 ( 0.001 to 0.102) 0.053 0.003 ( 0.001 to 0.007) 0.15 0.018 ( 0.043 to 0.078) 0.56 0.060 (0.009 to 0.111) 0.021
LVESD 0.089 (0.006 to 0.172) 0.036 0.005 ( 0.001 to 0.012) 0.091 0.087 ( 0.011 to 0.185) 0.082 0.079 ( 0.003 to 0.161) 0.058
IVSd  0.161 ( 0.297 to  0.025) 0.021  0.010 ( 0.021 to 0.000) 0.046 0.040 ( 0.121 to 0.201) 0.62 0.004 ( 0.130 to 0.139) 0.95
LVPW  0.178 ( 0.325 to  0.031) 0.019  0.005 ( 0.016 to 0.006) 0.35  0.010 ( 0.185 to 0.164) 0.91 0.020 ( 0.125 to 0.166) 0.78
LV-SF  0.058 ( 0.176 to 0.060) 0.33  0.004 ( 0.013 to 0.005) 0.38  0.168 ( 0.308 to  0.028) 0.020  0.008 ( 0.125 to 0.109) 0.89
CI 0.018 ( 0.156 to 0.191) 0.84  0.014 ( 0.028 to  0.001) 0.035  0.154 ( 0.359 to 0.051) 0.14 0.056 ( 0.116 to 0.227) 0.52
LVEDD¼left ventricular end diastolic diameter; LVESD¼left ventricular end systolic diameter; IVSd¼interventricular septum thickness; LVPW¼left ventricular posterior wall;
CI¼cardiac index; LV-FS¼left ventricular shortening fraction.
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sDISCUSSION
This study clearly demonstrates a frequent and progressive
valvular deterioration during the second decade after mediastinal
radiotherapy for Hodgkin’s lymphoma. Although the population
studied is biased towards patients with moderate valvular
regurgitation already present 10 years after treatment at ECHO
1993, 10 of 27 (37%) patients with no or mild aortic or mitral
regurgitation had in ECHO 2005 developed moderate aortic and/or
mitral regurgitation. Furthermore, after a median observation time
of 22 years, aortic stenosis was observed in 39%, developed after
1993 independently of the presence of regurgitation at ECHO 1993.
Even if the use of anthracyclines was associated with left
ventricular remodelling in the second decade after treatment this
study did not show any interaction between anthracyclines and the
development of valvular dysfunction.
Valvular dysfunction
Mediastinal radiotherapy is a known risk factor for the develop-
ment of cardiovascular diseases affecting the coronary arteries,
pericardium, myocardium, conduction system, and myocardial
valves (Lund et al, 1996; Hudson et al, 1998; Heidenreich et al,
2003, 2007; Hull et al, 2003; Adams et al, 2004; Aleman et al, 2007;
Swerdlow et al, 2007). One precipitating factor is believed to be
endothelial dysfunction, caused by an active cellular process
involving chronic inflammation resulting in reduced flow-
mediated vasodilatation in arteries within the radiation field
(Sugihara et al, 1999; Beckman et al, 2001). This dysfunction most
likely comprises reduced tissue endothelial nitric oxide synthase,
stimulation of growth factors, and fibrosis. Radiotherapy may also
directly damage the valves and cause fibrotic thickening, retrac-
tion, and calcifications (Basavaraju and Easterly, 2002). More
recently, decreased levels of endothelial progenitor cells has been
suggested to reduce endothelial regenerative capacity and to
contribute to the progression of degenerative aortic stenosis
(Matsumoto et al, 2009). Though valves are normally avascular,
cellular injury may cause fibrosis and stimulate secondary
angiogenesis and calcification. Our results suggest that valve
retraction is the predominant early change that causes valvular
regurgitation, and it takes as long as 20 years to develop thickened,
calcified valves that may finally result in stenosis. Higher pressure
on the left side of the heart likely explains the observation that the
aortic and mitral valves were affected more often than the tricuspid
or pulmonary valves, and that stenosis is primarily observed in the
aortic valve (Heidenreich et al, 2003; Hull et al, 2003; Adams et al,
2004). Previous reports have demonstrated that valvular calcifica-
tion is a dominant finding after mediastinal radiotherapy for
Hodgkin’s lymphoma (Adabag et al, 2004; Apter et al, 2006). This
study suggests that this occurs later in the development of valvular
pathology. Valvular calcification was seen among those with
moderate/severe valvular regurgitation/stenosis whereas leaflet
thickening and reduced movements without calcification were
seen among those with no or only mild valvular stenosis/
regurgitation. There was no evidence in this study of incipient
stenosis of the mitral valve.
CRP is a marker of future CAD and a level above 2.0mgl
 1 has
been shown to be associated with an increased risk of CAD (Ridker
et al, 2005). CRP was generally elevated in our group of HLSs,
especially in those with moderate and severe regurgitation
reflecting that a lasting inflammatory condition is initiated after
radiotherapy.
Pro-BNP as a marker of heart failure was elevated among
patients with moderate and severe valvular regurgitation, and
correlated positively with left ventricular end-systolic and
end-diastolic diameter as well as with decreased EF. None of the
patients had symptomatic heart failure, but valvular regurgitation
and signs of left ventricular remodelling sufficient to cause
elevated pro-BNP was a delayed consequence of treatment for
Hodgkin’s lymphoma.
The actual risk of valvular dysfunction in patients treated for
Hodgkin’s lymphoma is under debate. Aleman et al (2007)
observed a hazard ratio of 7.0 and a cumulative incidence of
approximately 10% for having clinically diagnosed valvular
disorder after a median observation time of 13 years in HLSs
treated with mediastinal radiotherapy. Hull et al (2003) reported
that 6% of 415 HLSs had clinically important valvular disorder 20
years after radiotherapy. Heidenreich et al, (2003) performed a
cross-sectional follow-up investigation in 73 patients 20 years after
radiotherapy with 12 (16%) cases of aortic stenosis, 11 (15%) cases
of moderate or severe aortic regurgitation, and 3 (4%) cases of
mitral regurgitation. This study demonstrates higher rates of
valvular regurgitation and aortic stenosis. These differences may
be due to study design (eg, identification of symptomatic disease
or screening methods), treatment differences (eg, field weighing,
shielding, use of anthracyclines), variable classification of valvular
dysfunction, varying sample sizes, and recruitment bias as well as
duration of follow-up. In particular, 24 patients in this study were
selected on the basis of their known moderate aortic and/or mitral
valvular regurgitation 10 years after treatment. However, even
among the 27 patients with no or mild aortic or mitral
regurgitation at 10 years of follow-up, we found comparable and
elevated rates of moderate valvular regurgitation (39%) which is
higher than expected from previous studies. Lund et al (1996)
found moderate valvular regurgitation to be more frequent in
women than in men. The high prevalence of valvular dysfunction
in this study might, at least in part, be due to the high percentage
of women (67%). This study demonstrated no additional effect of
anthracyclines on the development of valvular dysfunction
although this has been reported by another study (Aleman et al,
2007). Our study indicates that deterioration of valvular regurgita-
tion and the development of aortic stenosis are slow dynamic
processes that may appear more than 10 years after the diagnosis
of Hodgkin’s lymphoma. Importantly we could show that all aortic
stenosis developed after 1993 during the second and third
posttreatment decade.
The fact that patients had been informed about their individual
findings in ECHO 1993 may theoretically have changed the disease
course in our HLSs studied in ECHO 2005. The evolution of
valvular disease in patients with moderate regurgitation in 1993
may have been modified by treatment advice as a consequence of
the findings. We have no information about eventual post-1993
lifestyle adjustments and medical treatment in our patients.
Nevertheless, the majority of our patients were not followed
systematically with echocardiography as isolated moderate regur-
gitation or valvular stenosis in the absence of heart failure was not
treated medically. None, except the three patients with valvular
replacement, had symptomatic heart failure at the examination in
ECHO2005. Conversely, patients with no or mild regurgitation in
1993 may have paid less attention to lifestyle and cardiac
symptoms until ECHO 2005, provoking an acceleration of the
disease course. This suggestion is not supported by our data:
patients without or mild compared to moderate regurgitation
showed similar characteristics regarding comorbidities, cardiac
risk factors, and intervention for hypertension and hypercholes-
terolaemia. We therefore believe that our longitudinal findings, to
a large extent, mirror the ‘natural course’ of valvular function after
mediastinal radiotherapy for Hodgkin’s lymphoma.
Left ventricular function
Anthracyclines are associated with dose-dependent cardiotoxicity,
characterised by dilated cardiomyopathy and incipient heart
failure (Singal and Iliskovic, 1998; Meinardi et al, 2000; Belham
et al, 2007). The mechanisms underlying anthracycline-associated
myocardial damage are undefined, but a potential mechanism may
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2000; Wallace, 2003; Wouters et al, 2005). Our results consistently
demonstrated that treatment with low to intermediate doses of
anthracyclines were associated with thinning of ventricular walls
combined with an increase in ventricular dilatation compared to
radiotherapy alone or radiotherapy combined with chemotherapy
without anthracyclines. This is of relevance for the treatment
principles of stages I and II Hodgkin’s lymphoma even today, as
short-term anthracycline-based chemotherapy followed by in-
volved field radiotherapy (frequently encompassing parts of the
mediastinum) is still considered standard treatment for early-stage
disease in most Western countries (Ferme et al, 2007). To our
knowledge, this is one of the first studies to document a
progressive unfavourable effect of anthracyclines on cardiac
function two decades after the treatment of adult onset cancer.
Studies are underway which will evaluate the time-dependent
changes in cardiac function and examine the effect of an ACE-
inhibitor on myocardial performance, mainly in children with
different types of leukaemia and lymphomas (Singh et al, 1999;
Silber et al, 2004; Lipshultz et al, 2005).
Limitations
This study is limited by the small sample size and lack of a control
group of healthy individuals. This makes it difficult to estimate the
influence of age and other confounding factors and to relate our
findings to the general population. The Framingham population
between the ages of 40 and 60 years (Singh et al, 1999) displayed a
1% prevalence of moderate or severe mitral regurgitation in both
men and women, and a 0.4 and 0.1% prevalence of moderate or
severe aortic regurgitation in men and women, respectively. The
Framingham population does not directly correspond to the
Norwegian population. Nevertheless, our data, though biased
towards patients with valvular regurgitation 10 years after the
diagnosis of Hodgkin’s lymphoma, suggest an elevated risk of
premature valvular dysfunction among HLSs, not at least if
compared to Lund et al’s control group from 1993 where none of
40 age- and gender-matched controls displayed moderate valvular
regurgitation. The strength of our study was the longitudinal
follow-up design that enabled documentation of the slow
progressive nature of valvular dysfunction in individual patients
independent of valvular involvement at the first examination.
Conclusions
This study indicates that HLS treated with mediastinal radio-
therapy are at a high risk of developing progressive valvular
deterioration and subsequent aortic stenosis during the second or
third decade after treatment. Additional treatment with anthracy-
clines is associated with left ventricular remodelling. These
findings suggest that a strategy for cardiological follow-up should
be implemented for these patients considering the slowly evolving
cardiovascular side effects of radiotherapy and chemotherapy in
HLSs.
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